An Observational Study on Patients With Non-Squamous NSCLC Who Reached A Long PFS After Avastin (Bevacizumab)-Based First-Line Therapy

Retrospective Study to Determinate the Clinical Phenotype of Patients With Non Squamous NSCLC Treated With First Line Bevacizumab-based Therapy That Reached a Long PFS

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01343914

Enrollment

118

Registered

2011-04-28

Start date

2011-06-30

Completion date

2011-12-31

Last updated

2016-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Brief summary

This retrospective observational study will analyse demographic, clinical and treatment-related data of patients with non-squamous non-small cell lung cancer (NSCLC) who had reached \>/= 9 months of progression-free survival after Avastin (bevacizumab)-based first-line therapy. Data will be collected for approximately 9 months.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients, \>/= 18 years of age * Non-squamous non-small cell lung cancer (NSCLC) treated with first-line Avastin-based therapy * Progression-free survival of \>/= 9 months reached

Exclusion criteria

* N/A

Design outcomes

Primary

Measure	Time frame
Progression-free survival (>9 months) according to clinical phenotype	approximately 9 months

Secondary

Measure	Time frame
Overall survival	approximately 9 months
Safety: Incidence of adverse events	approximately 9 months

Countries

Spain

Outcome results